LOGC - LogicBio Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5182.93M
Enterprise Value 3120.24M
Trailing P/E N/A
Forward P/E 1-3.94
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.87
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-3.96

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3∞%
S&P500 52-Week Change 3-0.33%
52 Week High 320.07
52 Week Low 36.70
50-Day Moving Average 311.53
200-Day Moving Average 311.74

Share Statistics

Avg Vol (3 month) 318.76k
Avg Vol (10 day) 323.63k
Shares Outstanding 522.49M
Float 5.29M
% Held by Insiders 126.97%
% Held by Institutions 164.58%
Shares Short (Jul 31, 2019) 4115.52k
Short Ratio (Jul 31, 2019) 414.52
Short % of Float (Jul 31, 2019) 41.43%
Short % of Shares Outstanding (Jul 31, 2019) 40.51%
Shares Short (prior month Jun 28, 2019) 4110.44k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-43.27%
Return on Equity (ttm)-71.69%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -30.35M
Net Income Avi to Common (ttm)-24.84M
Diluted EPS (ttm)-1.55
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)63.66M
Total Cash Per Share (mrq)2.81
Total Debt (mrq)967k
Total Debt/Equity (mrq)1.52
Current Ratio (mrq)14.24
Book Value Per Share (mrq)2.82

Cash Flow Statement

Operating Cash Flow (ttm)-25.91M
Levered Free Cash Flow (ttm)-16.85M